Author

T. R. Gershon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Organism:mouse· 3 Assay:scRNA-seq· 3 Approach:deep learning· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

T. Dismuke· 3 shared C. Lim· 2 shared D. S. Malawsky· 2 shared A. Garancher· 1 shared A. M. Donson· 1 shared A. M. Griesinger· 1 shared A. Nellan· 1 shared A. Tikunov· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

T. Dismuke

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeting OLIG2 increases therapeutic responses in SHH medulloblastoma mouse models and patient-derived medulloblastoma organoids

Y. Li, T. Dismuke, C. Lim, Z. C. Bruce, C. Offenhauser, U. Baumgartner, M. Maybury, R. C. J. DSouza, T. Hassall, B. Wainwright, G. Stein, M. Piper, T. G. Johns, M. Sokolsky-Papkov, T. R. Gershon, B. W. Day

This study shows that targeting OLIG2 with CT-179 reduces recurrence in SHH medulloblastoma models and improves survival when combined with radiotherapy.

bioRxiv · Feb 14, 2022 · PreprintCancer Biology

Chronic AMPK inactivation slows SHH medulloblastoma progression by inhibiting mTORC1 signaling and depleting tumor stem cell populations

T. Dismuke, D. S. Malawsky, H. Liu, J. Brenman, B. Dasgupta, A. Tikunov, T. R. Gershon

This study shows that inactivating AMPK in medulloblastoma models slows tumor progression by reducing tumor stem cells and mTORC1 activity.

bioRxiv · Dec 9, 2021 · PreprintCancer Biology

Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib

C. Lim, T. Dismuke, D. Malawsky, J. D. Ramsey, D. Hwang, V. L. Godfrey, A. V. Kabanov, T. R. Gershon, M. Sokolsky

This study improves CDK4/6 inhibitor therapy for medulloblastoma by combining nanoparticle delivery with scRNA-seq-guided identification of sapanisertib, enhancing survival in mice.

bioRxiv · Jun 9, 2021Cancer Biology

Neoplastic and Immune single cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.

K. A. Riemondy, S. Venkataraman, N. Willard, A. Nellan, B. Sanford, A. M. Griesinger, V. Amani, S. Mitra, T. C. Hankinson, M. H. Handler, M. Sill, J. Ocasio, S. J. Weir, D. S. Malawsky, T. R. Gershon, , R. Vibhakar

The paper uses single-cell transcriptomics to identify subgroup-specific neoplastic and immune cell heterogeneity in childhood medulloblastoma.

bioRxiv · Aug 28, 2020Cancer Biology